Parameters spanning age, sex, tumor classifications encompassing IDH mutation status and distinct GBM subtypes, as well as the therapeutic modalities of chemotherapy and radiotherapy, were critically engaged in this multifaceted endeavor. The gene discussed is IDH1; the disease is glioblastoma.